ArticleJournal of translational medicine2026
Self-supervised graph contrastive learning for scRNA-seq clustering.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSingle-cell RNA sequencing (scRNA-seq) enables characterization of cellular heterogeneity, but accurate and stable clustering remains challenging due to high dimensionality, sparsity, and technical noise. Many existing methods insufficiently exploit intrinsic cell-cell relationships and latent cell-type signals, leading to suboptimal representations and unstable assignments. The objective of this study is to develop a self-supervised graph contrastive framework for scRNA-seq clustering that jointly leverages augmented views, intrinsic cell-cell relationships, and pseudo-label-guided graph refinement to improve clustering robustness and biological interpretability.
methodsWe propose Self-Supervised Contrastive Graph Learning (SSGL), which refers specifically to the proposed scRNA-seq clustering framework and not to a generic or pre-existing method. SSGL generates two augmented views of each cell via dual random gene masking, then learns representations with a momentum-encoder architecture. A refined cell-cell graph is constructed by intersecting a k-nearest-neighbor similarity graph with pseudo-label consistency, and a graph-aware contrastive objective enforces agreement between augmented views while preserving local neighborhood structure.
resultsWe evaluated SSGL on eight public scRNA-seq benchmarks spanning different tissues and sequencing platforms, and compared it with representative clustering baselines using NMI and ARI. Across all datasets, SSGL achieved the best overall clustering performance, with average NMI = 0.876 and average ARI = 0.926, outperforming competing approaches and showing more consistent results across heterogeneous datasets. Relative to AttentionAE-SC, the strongest overall baseline based on the averaged results, SSGL improved the average NMI and ARI by approximately 4.4% and 6.7%, respectively. Ablation analyses demonstrated that incorporating the self-supervised refined graph improves clustering beyond conventional contrastive objectives. Visualization and marker-gene analyses further supported that SSGL yields compact, well-separated clusters and recovers biologically coherent cell groups, including rare populations.
conclusionsSSGL improves scRNA-seq clustering accuracy and stability by jointly leveraging augmented views, intrinsic cell-cell relationships, and pseudo-label-guided graph refinement within a graph contrastive learning framework. This provides robust representations that support reliable cell-type discovery and downstream biological interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.